[ad_1]
Original title: The CIIE ended successfully, the reporter will show you the four novelties of this year
The third CIIE came to an end. At the medical museum, in addition to showcasing the world’s latest black tech achievements, such as new drugs and equipment, like the previous two CIIEs, a Health Times reporter found that this year’s CIIE There are also these four new developments, which will have a significant impact on the pharmaceutical industry.
The national team takes the lead, the provincial team organizes a group to buy, buy and buy
“Science and technology are sharp weapons for human beings to fight disease. Faced with the new corona epidemic, new products and technologies such as biomedicine, information technology, artificial intelligence and big data have played an important role, providing the general promotion of epidemic prevention and control and economic and social development. He Jinguo, deputy head of the trade delegation of the National Health Commission and director of the Finance Department, said that 50 dependent hospitals of the National Health Commission and the State Administration of Traditional Chinese Medicine have entered the market as the “national team” of China’s health industry Expo.
“In the last three years, the number of commercial delegations in our committee has increased from 55 in the first session to 132 in the third session. The amount of the transaction has increased from 477 million dollars in the first session to 641 million dollars. dollars in the second session. The amount will increase compared to the second, and the scale and quality of the transaction have always remained at a high level and have been increasing year after year. It is to make the most of the CIIE stage , exchange advanced ideas with peers and related fields, and purchase advanced product technology. “
At the same time, this year many provincial governments, including Shandong and Tianjin, are interested in the high technology of the CIIE. Taking medicine and health as an example, Professor Hao Xiaoke, President of the Shaanxi Institute of Laboratory Medicine and Director of the Xijing Hospital Clinical Laboratory Medicine Laboratory, was witnessed by the Vice Governor of Shaanxi Province, representing the Shaanxi Province’s main project: Xi’an Regional Inspection Center. Danaher places an order. “This project covers Xi’an, and is the first in China to establish a regional inspection center in a provincial capital.” Hao Xiaoke said that not only the new corona, influenza or other infectious diseases, but also foreign platforms and technology construction methods The cabin laboratory has a daily testing capacity of 500,000 to 1 million after mixing samples, which can meet large-scale tests that a single hospital cannot solve.
Chinese local R&D products occupy the booth of foreign companies
After touring the booth related to cardiovascular equipment, Academician Ge Junbo, chairman of the cardiovascular physicians branch of the China Association of Physicians, arrived at the Boston Scientific booth and stopped: it turns out that here is an optical coherence tomography system cardiovascular (OCT). Shenzhen Zhongke Microlight Medical Device Technology Co., Ltd. company researched and developed, but was favored by Poco and entered Poko Expo booth. This cooperation is one of the successful incubation projects of the China CCI Cardiovascular Doctors Innovation Club, a five-year-old cardiovascular innovation transformation platform.
At the round table on “China Power Grafting with International Resources and CCI Models” organized by Fosun Health +, Academician Ge Junbo interpreted the process of successful emergence of this research and development at CIIE: The establishment of CCI in 2015 and his personal presidency is to promote the foundation. Cross-border integration of research, materials science and engineering experts to solve clinical problems.
Academician Ge Junbo said: “As the first strategic alliance of foreign-funded companies and local companies in the field of interventional coronary imaging, I believe that both sides can use their respective advantages to accelerate the implementation of the concept of ‘Precision PCI ‘under the guidance of intracavitary images and provide patients with more comprehensive treatments. Plan. I am also very happy that this new cooperation model is promoted by the CCI platform, which has expanded new development ideas for local innovative companies and companies with foreign funding. “
“Foreign companies set the stage, the local circle of friends sing”
During CIIE, many foreign companies signed strategic cooperation agreements with local Chinese companies, but Cytiva, a “7 months” company, stood out: it signed multiple strategic agreements with 4 local companies at the same time. . These include the announcement of cooperation with Weigao Pharmaceuticals to start the expansion project for the production of disposable consumables for bioprocesses, the strategic cooperation between Cytiva and Zhifei Biology and the update to comprehensively improve the vaccine localization process, and the signing of a Cooperation agreement between Cytiva and Clover Biology to accelerate Clover Biology “S- In the clinical research and production of new corona” trimer “vaccine candidates, Cytiva and Jinbo Biosciences jointly established a joint laboratory for new humanized materials to continue promoting industrial innovation .
Although it only joined the Danaher Group in April this year, Cytiva’s predecessor was GE Biomedicine, which has a history of hundreds of years. Therefore, it has a broad product portfolio in the fields of bioprocess development, bioprocess enhancement, protein research, research and development, and vaccine production. .
Ms. Yu Lihua, General Manager of Cytiva Greater China, said that Cytiva has cooperation with the top five lines of vaccine research and development in the world. Among them, Cytiva provides solutions and platforms for global clinical trial phase biopharmaceutical companies such as Clover Bio, which is focused on developing innovative vaccines and biologic therapies, and helping their new corona “S-trimer” vaccine candidates to realize Phase I clinical trials The subsequent expansion of the production scale; For domestic mature vaccine companies such as Zhifei, Cytiva’s product technology and services will further help Zhifei Biology implement human vaccines, human therapeutic antibodies and cell therapy and other lines of research and development to accelerate clinical application. To achieve commercial production and benefit more patients, Cytiva also cooperates with Jinbo Biology, an international leader in the field of genetic engineering of new recombinant humanized biological materials, to create a “joint laboratory of new humanized collagen material”.
“The circle of friends we have created is also an ecosystem of industry, academia and research. This is also to realize our vision, accelerate the availability of innovative reforms and therapies and promote a healthy future for humanity.”
C public health station position, emphasizing more prevention
The new corona epidemic has highlighted the importance of disease prevention and the important value of vaccines for disease prevention and control. The status of the entire infectious disease has improved. In the past, new drugs and products were eye-catching, but this year vaccines and epidemic prevention kits have become hugely successful. In addition to the publication of new information on the corona vaccine, there is no shortage of articles related to the vaccine. GSK’s shingles vaccine and proprietary adjuvant technology were very popular at the booth. Ms. Qi Xin, general manager of prescription drugs and vaccines at GSK China, introduced that the new product that was showcased last year has been vaccinated with this vaccine in more than 30 Chinese cities, including Beijing, Shanghai, Guangzhou and Shenzhen.
An Sijia, Chairman of Xi’an Janssen Pharmaceutical Co., Ltd., introduced that in addition to working hard to develop solutions for the new corona pneumonia, Xi’an Janssen is also a strong partner in China’s fight against tuberculosis. multidrug-resistant (MDR-TB), and it is the country’s goal to “end the tuberculosis epidemic by 2035.” give support. In addition to introducing the first new type of TB drug approved by China in more than 40 years, we are also committed to helping identify TB patients. “We started a project aimed at detecting MDR-TB cases in 10 million people in 22 poverty-stricken counties in three central and western provinces, Jiangxi, Shaanxi and Shanxi. We are committed to improving the diagnosis of tuberculosis, especially tuberculosis resistant to the drugs. “
“Two of Johnson & Johnson’s nine drug discovery and development centers are located in China, and one of Johnson & Johnson’s four regional innovation centers is located in China.” “This year we will allow China to participate in more than 50% of Pfizer’s global plans. Our vision is until 2022. Let China participate in more than 80% of Pfizer’s global plans and allow the world to approve new drugs and vaccines around the same time. This will benefit patients in China and around the world. ” Additionally, at the CIIE, both Johnson & Johnson and Pfizer voiced the voice of many foreign companies. : In a special year, participating in this CIIE is to remain optimistic about China and continue to increase investment in R&D in China.
